A patient with confirmed acute ischemic stroke is eligible for fibrinolytics. What is the appropriate alteplase dose based on his weight?

The appropriate alteplase dose for a patient with confirmed acute ischemic stroke who is eligible for fibrinolytics is correctly described in the choice that involves delivering 9 mg as a bolus, followed by an infusion of 81 mg over an hour. This dosing adheres to the established protocol for administering alteplase in the setting of acute ischemic stroke.

The total dose of alteplase is typically 0.9 mg per kilogram of body weight, with a maximum dose capped at 90 mg. This dosing regimen is designed to ensure effective thrombolysis while minimizing the risk of hemorrhage. The initial bolus of 10% of the total dose is administered intravenously over 1 minute, followed by the remainder infused over the next hour. Thus, for a patient whose total dose calculated based on their weight conforms to this regimen, administering a bolus of 9 mg and an additional 81 mg in an hour aligns perfectly with these guidelines.

Understanding this dosing approach is crucial for safe and effective management of acute ischemic stroke and highlights the importance of adhering to clinical guidelines for thrombolitic therapy. Recognizing the correct dosing strategy is essential for achieving optimal outcomes in patients with this condition.